Mortality from adverse drug reactions in adult medical inpatients at four hospitals in South Africa: A cross-sectional survey

British Journal of Clinical Pharmacology

Volumn 80, Issue 4, 2015, Pages 818-826

  Mouton, Johannes P ^a   Mehta, Ushma ^a,b   Parrish, Andy G ^c   Wilson, Douglas P K ^d   Stewart, Annemie ^a   Njuguna, Christine W ^a   Kramer, Nicole ^a   Maartens, Gary ^a   Blockman, Marc ^a   Cohen, Karen ^a  

^a UNIVERSITY OF CAPE TOWN   (South Africa)

^b Independent Pharmacovigilance Consultant   (South Africa)

^c WALTER SISULU UNIVERSITY   (South Africa)

^d EDENDALE HOSPITAL   (South Africa)

Author keywords

adverse drug reaction; anti tuberculosis therapy; antiretroviral therapy; in hospital death; preventability; South Africa

Indexed keywords

ANALGESIC AGENT; ANGIOTENSIN ANTAGONIST; ANTICOAGULANT AGENT; ANTIFUNGAL AGENT; ANTIGOUT AGENT; ANTIHYPERTENSIVE AGENT; ANTIINFECTIVE AGENT; ANTIINFLAMMATORY AGENT; ANTIMYCOBACTERIAL AGENT; ANTINEOPLASTIC AGENT; ANTIRHEUMATIC AGENT; ANTIVIRUS AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BLOOD SUBSTITUTE; CALCIUM CHANNEL BLOCKING AGENT; CORTICOSTEROID; COTRIMOXAZOLE; DIURETIC AGENT; IMMUNOSUPPRESSIVE AGENT; RIFAMPICIN; TENOFOVIR;

ADULT; AGED; COMORBIDITY; CROSS-SECTIONAL STUDY; DRUG FATALITY; EPILEPSY; FEMALE; HEALTH SURVEY; HOSPITAL ADMISSION; HOSPITAL PATIENT; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; MIDDLE AGED; MORTALITY; PRIORITY JOURNAL; REVIEW; SCORING SYSTEM; SOUTH AFRICA; TUBERCULOSIS; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; EPIDEMIOLOGY; HOSPITAL; RISK FACTOR; STATISTICS AND NUMERICAL DATA; YOUNG ADULT;

ADULT; AGED; CROSS-SECTIONAL STUDIES; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; FEMALE; HOSPITALS; HUMANS; INPATIENTS; MALE; MIDDLE AGED; RISK FACTORS; SOUTH AFRICA; YOUNG ADULT;

EID: 84942515576     PISSN: 03065251     EISSN: 13652125     Source Type: Journal    
DOI: 10.1111/bcp.12567     Document Type: Review

References (25)

1. Wester K, Jönsson AK, Spigset O, Druid H, Hägg S,. Incidence of fatal adverse drug reactions: a population based study. Br J Clin Pharmacol 2008; 65: 573-579.
2. Lazarou J, Pomeranz BH, Corey PN,. Incidence of adverse drug reactions in hospitalized patients: a meta-analysis of prospective studies. JAMA 1998; 279: 1200-1205.
3. Buajordet I, Ebbesen J, Erikssen J, Brørs O, Hilberg T,. Fatal adverse drug events: the paradox of drug treatment. J Intern Med 2001; 250: 327-341.
4. Ebbesen J, Buajordet I, Erikssen J, Brørs O, Hilberg T, Svaar H, Sandvik L,. Drug-related deaths in a department of internal medicine. Arch Intern Med 2001; 161: 2317-2323.
5. Juntti-Patinen L, Neuvonen PJ,. Drug-related deaths in a university central hospital. Eur J Clin Pharmacol 2002; 58: 479-482.
6. Davies EC, Green CF, Taylor S, Williamson PR, Mottram DR, Pirmohamed M,. Adverse drug reactions in hospital in-patients: a prospective analysis of 3695 patient-episodes. PLoS ONE 2009; 4: e4439.
7. Mehta U, Durrheim DN, Blockman M, Kredo T, Gounden R, Barnes KI,. Adverse drug reactions in adult medical inpatients in a South African hospital serving a community with a high HIV/AIDS prevalence: prospective observational study. Br J Clin Pharmacol 2008; 65: 396-406.
8. UNAIDS. Global Report: UNAIDS Report on the Global AIDS Epidemic 2013. Geneva: UNAIDS, 2013.
9. World Health Organisation. Global Tuberculosis Report. Geneva: World Health Organisation, 2013.
10. Aronson JK, Ferner RE,. Clarification of terminology in drug safety. Drug Saf 2005; 28: 851-870.
11. Rozich JD, Haraden CR, Resar RK,. Adverse drug event trigger tool: a practical methodology for measuring medication related harm. Qual Saf Health Care 2003; 12: 194-200.
12. World Health Organization. The use of the WHO-UMC system for standardized case causality assessment [Internet]. Uppsala: The Uppsala Monitoring Centre. Available at http://who-umc.org/Graphics/24734.pdf (last accessed 17 March 2014).
13. Schumock GT, Thornton JP,. Focusing on the preventability of adverse drug reactions. Hosp Pharm 1992; 27: 538.
14. Quan H, Sundararajan V, Halfon P, Fong A, Burnand B, Luthi J-C, Saunders LD, Beck CA, Feasby TE, Ghali WA,. Coding algorithms for defining comorbidities in ICD-9-CM and ICD-10 administrative data. Med Care 2005; 43: 1130-1139.
15. Zavascki AP, Fuchs SC,. The need for reappraisal of AIDS score weight of Charlson comorbidity index. J Clin Epidemiol 2007; 60: 867-868.
16. Pirmohamed M, James S, Meakin S, Green C, Scott AK, Walley TJ, Farrar K, Park BK, Breckenridge AM,. Adverse drug reactions as cause of admission to hospital: prospective analysis of 18 820 patients. BMJ 2004; 329: 15-19.
17. Zoppi M, Braunschweig S, Kuenzi UP, Maibach R, Hoigné R,. Incidence of lethal adverse drug reactions in the comprehensive hospital drug monitoring, a 20-year survey, 1974-1993, based on the data of Berne/St. Gallen. Eur J Clin Pharmacol 2000; 56: 427-430.
18. Qing-ping S, Xiao-dong J, Feng D, Yan L, Mei-ling Y, Jin-xiu Z, Shu-qiang Z,. Consequences, measurement, and evaluation of the costs associated with adverse drug reactions among hospitalized patients in China. BMC Health Serv Res 2014; 14: 73.
19. Lobo MGADA, Pinheiro SMB, Castro JGD, Momenté VG, Pranchevicius M-CS,. Adverse drug reaction monitoring: support for pharmacovigilance at a tertiary care hospital in Northern Brazil. BMC Pharmacol Toxicol 2013; 14: 5.
20. Noblat ACB, Noblat LACB, Toledo LAK de, Santos P de M, Oliveira MG de, Tanajura GM, Spinola SU, Almeida JRM de,. Prevalence of hospital admission due to adverse drug reaction in Salvador, Bahia. Rev Assoc Med Bras 2011; 57: 42-45.
21. Zargarzadeh AH, Emami MH, Hosseini F,. Drug-related hospital admissions in a generic pharmaceutical system. Clin Exp Pharmacol Physiol 2007; 34: 494-498.
22. Vora MB, Trivedi HR, Shah BK, Tripathi CB,. Adverse drug reactions in inpatients of internal medicine wards at a tertiary care hospital: a prospective cohort study. J Pharmacol Pharmacother 2011; 2: 21-25.
23. Raut A, Diwan A, Patel C, Patel P, Pawar A,. Incidence, severity and financial burden associated with adverse drug reactions in medicine inpatients. Asian J Pharm Clin Res 2011; 4: 103-111.
24. World Health Organisation. Consolidated Guidelines on the Use of Antiretroviral Drugs for Treating and Preventing HIV Infection: Recommendations for A Public Health Approach. Geneva: World Health Organisation, 2013.
25. Cooper RD, Wiebe N, Smith N, Keiser P, Naicker S, Tonelli M,. Systematic review and meta-analysis: renal safety of tenofovir disoproxil fumarate in HIV-infected patients. Clin Infect Dis 2010; 51: 496-505.